Mounjaro vs Zepbound: same molecule, different approval
Mounjaro and Zepbound are the same drug — tirzepatide, from Eli Lilly — approved under two different names for two different indications. The difference determines your insurance coverage and out-of-pocket cost.
Mounjaro and Zepbound both contain tirzepatide at identical doses. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved for chronic weight management and obstructive sleep apnea. Because Medicare and many commercial plans cover diabetes drugs but exclude weight-loss drugs, Mounjaro is often covered when Zepbound is not — even though the molecule is the same. Neither is a compounded product.
At a glance
| Attribute | Mounjaro | Zepbound |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide (identical) |
| Maker | Eli Lilly | Eli Lilly |
| FDA indication | Type 2 diabetes | Weight management; obstructive sleep apnea |
| Trial evidence | SURPASS (diabetes) | SURMOUNT (weight) |
| List price/mo | ~$1,069 | ~$1,086 |
| Medicare | Covered for T2D | Excluded for weight loss |
Which one applies to you
You do not choose between Mounjaro and Zepbound as products — your diagnosis and your prescriber determine which one is appropriate. If you have type 2 diabetes, Mounjaro is the labeled product and is far more likely to be covered by insurance, including Medicare Part D. If you are treating obesity or obstructive sleep apnea without diabetes, Zepbound is the labeled product, but it faces the statutory Medicare weight-loss exclusion and variable commercial coverage. The molecule and its effects are identical; the label, the coverage, and the price pathway differ.
How compounded tirzepatide fits
Compounded tirzepatide is a separate, non-FDA-approved category that some telehealth programs offer at $199–$297/month, far below either brand’s list price. It carries none of the SURMOUNT or SURPASS trial evidence and is legally restricted after the 2025 shortage resolution. See our tirzepatide cost guide and compounded tirzepatide guide.
Sources
- FDA — Mounjaro and Zepbound labels (Drugs@FDA). accessdata.fda.gov
- SURMOUNT and SURPASS trial programmes, NEJM.